David Badawi Sells 3,128 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,128 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $6.42, for a total transaction of $20,081.76. Following the sale, the chief technology officer now owns 1,759,648 shares of the company’s stock, valued at approximately $11,296,940.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Sight Sciences Price Performance

Shares of NASDAQ SGHT traded up $0.03 during trading on Wednesday, hitting $6.19. 76,060 shares of the company were exchanged, compared to its average volume of 200,831. The company has a market cap of $307.99 million, a price-to-earnings ratio of -5.53 and a beta of 2.75. Sight Sciences, Inc. has a 1 year low of $1.04 and a 1 year high of $9.31. The firm’s fifty day moving average price is $6.07 and its 200 day moving average price is $5.26. The company has a debt-to-equity ratio of 0.31, a current ratio of 13.01 and a quick ratio of 12.42.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Thursday, May 2nd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.04). The company had revenue of $19.27 million for the quarter, compared to analysts’ expectations of $18.34 million. Sight Sciences had a negative return on equity of 44.45% and a negative net margin of 67.18%. On average, sell-side analysts expect that Sight Sciences, Inc. will post -1.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Institutional investors have recently made changes to their positions in the stock. RTW Investments LP purchased a new stake in shares of Sight Sciences during the 4th quarter worth $850,000. UBS Group AG boosted its position in shares of Sight Sciences by 20,282.6% in the 4th quarter. UBS Group AG now owns 2,895,958 shares of the company’s stock worth $14,943,000 after buying an additional 2,881,750 shares in the last quarter. Panagora Asset Management Inc. boosted its position in shares of Sight Sciences by 198.1% in the 4th quarter. Panagora Asset Management Inc. now owns 59,190 shares of the company’s stock worth $305,000 after buying an additional 39,333 shares in the last quarter. Jackson Square Partners LLC boosted its position in shares of Sight Sciences by 12.0% in the 4th quarter. Jackson Square Partners LLC now owns 1,629,746 shares of the company’s stock worth $8,409,000 after buying an additional 174,737 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of Sight Sciences by 180.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 12,076 shares of the company’s stock worth $62,000 after buying an additional 7,764 shares in the last quarter. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

SGHT has been the subject of several recent analyst reports. Piper Sandler restated a “neutral” rating and set a $6.00 price objective (up previously from $5.00) on shares of Sight Sciences in a research report on Friday, May 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, May 3rd. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Sight Sciences presently has a consensus rating of “Hold” and a consensus price target of $4.70.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.